Integral Role of Nutrition in CCA

June 2024, Vol 5, No 2

Nutrition is an integral part of cancer care, particularly for cancer of gastrointestinal origin, such as cholangiocarcinoma (CCA).1

At the 2024 Cholangiocarcinoma Foundation Annual Conference, Shelby Yaceczko, MS, RDN-AP, CNSC, an advanced practice dietitian nutritionist, reviewed nutrient metabolism relevant to CCA, nutrition impact symptoms during CCA treatment, and diet principles to follow.

At the outset, Ms Yaceczko stressed the importance of nutrition and that it is often not prioritized or overlooked during disease management. She noted, “If we get a diagnosis of a life-changing condition [such as CCA], we often forget that if we don’t have the proper fuel and are not eating and nourishing our body, we cannot get to the next step.”

Nutrition-impact symptoms may arise due to the disease itself and/or those emergent with CCA treatment, including surgery and chemotherapy, and the role of nutrition in CCA largely focuses on managing these related symptoms.

Ms Yaceczko stated that the disease and/or treatment can affect appetite and food interest, impacting overall nutrition. Moreover, nutritional needs are dynamic and can change during the disease, with nutritional status worsening as it progresses. She recommended maintaining a nutritional log during the cancer continuum to better track diets that worked well and those that compromised nutrition to make necessary adjustments.

Inadequate nutrition over time can lead to malnutrition, which is associated with negative outcomes, such as feeling tired and weak, and may make the patient unable to complete cancer therapy or fight infection. Therefore, the main goals of nutritional interventions are to maintain energy and overall well-being, eat a balanced diet focused on nutrient-dense foods for fuel, prevent loss of muscle mass, and maintain defenses against infection.

Nutrition-impact symptoms may be specific to the CCA treatment received, including the type of surgery (eg, removal of bile ducts, partial liver resection, Whipple procedure, liver bypass, liver transplantation, stent placement), chemotherapy, radiation, and combination therapy.

Nutritional considerations after surgery include delayed gastric emptying, diabetes, malabsorption, malnutrition, loss of appetite, early satiety, abdominal discomfort, altered bowel habits, and pancreatic insufficiency.

Nutritional considerations during cancer treatment include loss of appetite, mouth sores, dry mouth, unintentional weight loss, vomiting, diarrhea and/or constipation, taste or smell changes, and nausea.

Ms Yaceczko made suggestions for improving appetite, such as making mealtime more social, honoring daily food preferences, trying favorite foods, and recreating settings that will make the patient eat more consistently and more frequently instead of just pressurizing them to eat, and replacing liquid meals with more solid foods.2

References

  1. Hormati A, Hajrezaei Z, Jazi K, et al. Gastrointestinal and pancreatic hepatobiliary cancers: a comprehensive review on epidemiology and risk factors worldwide. Middle East J Dig Dis. 2022;14(1):5-23.
  2. Yaceczko S. Nutrition and cholangiocarcinoma: what’s the scoop? Cholangiocarcinoma Foundation 2024 Annual Conference. Presented April 17-19, 2024. Accessed June 6, 2024.

Related Items

Biomarker Discovery and Early Detection in CCA
June 2025, Vol 6, No 2
Experts unveiled a roadmap for translating cutting-edge biomarkers into clinical practice, paving the way for improved early detection and personalized care in high-risk populations with cholangiocarcinoma (CCA).
Translational Science and Discovery in CCA
June 2025, Vol 6, No 2
Leading experts explored groundbreaking advancements in tumor microenvironments, biomarker validation, and innovative therapies, paving the way for transformative precision medicine in cholangiocarcinoma (CCA) care.
Advancements in Cholangiocarcinoma Diagnosis and Treatment: Radiomics, Biomarkers, and Optimal Biliary Decompression
June 2025, Vol 6, No 2
Cutting-edge advancements in tumor microenvironments, therapeutic resistance, biomarker validation, and innovative treatments are paving the way for breakthroughs in precision medicine.
Pathology in CCA
June 2025, Vol 6, No 2
Experts in cholangiocarcinoma (CCA) have explored the transformative role of artificial intelligence in improving CCA diagnosis, predictive marker identification, and understanding precursor lesions to advance targeted therapies and personalized care.
Locoregional Therapies and Radiation for the Treatment of Patients With CCA
June 2025, Vol 6, No 2
Experts have highlighted the latest advancements in locoregional treatments, including hepatic arterial infusion, selective internal radiation therapy, ablation techniques, and histotripsy, offering new hope for improving survival in cholangiocarcinoma (CCA) patients.
Systemic Therapies and Surgery for CCA
June 2025, Vol 6, No 2
Experts discuss advancements in systemic therapies, surgical strategies, and liver transplantation, offering new hope for improving outcomes in patients with cholangiocarcinoma (CCA).
Tinengotinib: A Next-Generation Fibroblast Growth Factor Receptor (FGFR) Inhibitor for CCA
June 2025, Vol 6, No 2
Tinengotinib emerged as a promising next-generation multikinase inhibitor, offering new hope for patients with resistant cholangiocarcinoma (CCA) through its innovative mechanism of action and encouraging clinical trial results.
Advancing Oncology Research Through Novel Endpoints and Consensus-Driven Collaboration
June 2025, Vol 6, No 2
A collaborative roadmap has been unveiled to redefine clinical endpoints, advance precision medicine, and align global efforts in tackling the challenges of rare and aggressive biliary tract cancers.
AI-Driven Approaches in CCA
June 2024, Vol 5, No 2
Three presentations discussed the application of artificial intelligence learning– and machine learning-driven approaches to improve pathology, radiology, and drug discovery processes, showing strong potential for improving outcomes in patients with cholangiocarcinoma.
Cancer Vaccines Targeting WT1 for CCA
June 2024, Vol 5, No 2
Benjamin L. Green, MD, presented Wilms’ tumor 1 vaccine novel adoptive cell therapy approaches for advanced solid cancers, including the role of immunotherapy in treating advanced cholangiocarcinoma.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Profession or Role
Primary Specialty or Disease State